10x Genomics, Inc. (Nasdaq: TXG), a life sciences technology leader in single cell and spatial biology, has unveiled a new product and a strategic acquisition within days of each other, underlining its push to dominate the next phase of cellular and tissue-level analysis. On August 19, 2025, the company launched Xenium Protein, the first fully integrated spatial multiomic assay on its Xenium platform, enabling simultaneous RNA and protein detection within the same cell. Earlier this month, 10x Genomics also announced the acquisition of Scale Biosciences, Inc., a specialist in scalable single cell analysis, for $30 million in cash and stock, with potential milestone-based payouts.
These two moves, combined with solid second-quarter financial results, highlight how 10x Genomics is consolidating its innovation roadmap and strengthening its role as the key supplier for multiomic insights that support cancer research, immunology, and neuroscience.
How does the launch of Xenium Protein expand the potential of spatial multiomic research workflows for disease discovery?
The launch of Xenium Protein marks a milestone for spatial biology. Traditionally, researchers had to run separate workflows for RNA and protein profiling, then attempt to co-register the datasets — a process prone to integration errors and interpretive uncertainty. 10x Genomics’ new product removes this barrier by allowing both RNA and protein data to be captured in situ on the same tissue section and in a single automated run.
Michael Schnall-Levin, founding scientist and Chief Technology Officer of 10x Genomics, emphasized that integrated multiomics is no longer optional but essential for understanding disease biology at the cellular level. He explained that the platform allows researchers to streamline workflows and cut down on time-to-insight, accelerating translational applications in oncology and immunology.
The initial release includes ready-to-use protein subpanels covering dozens of markers related to cell growth, immune activation, and signaling pathways — areas that are central to cancer and autoimmune research. Early access adopters, including pharmaceutical firms, have indicated that the approach is already proving valuable for target validation and biomarker discovery.
Dr. Julien Tessier, a principal scientist at Sanofi, was cited as saying that combining RNA and protein profiling in one workflow delivers a “comprehensive view of tissue architecture” while eliminating the uncertainty of data stitching. For 10x Genomics, this is a direct response to researchers’ demand for platforms that accelerate discovery while maintaining reproducibility and confidence.
Why is the acquisition of Scale Biosciences a strategic bet on single cell scalability and affordability?
Alongside its multiomic expansion, 10x Genomics is bolstering its core Chromium platform with the purchase of Scale Biosciences, a company known for its innovations in combinatorial indexing and quantum barcoding. These methods allow researchers to analyze vastly greater numbers of cells and samples at a fraction of the cost, directly addressing a bottleneck in scaling single cell genomics.
The $30 million upfront deal, with additional milestone-based considerations, brings Scale’s intellectual property and scientific founders into 10x’s orbit. Garry Nolan of Stanford University, Jay Shendure and Cole Trapnell of the University of Washington, and Frank Steemers are joining as advisors to integrate their indexing methods with 10x’s product pipeline.
10x Genomics’ CEO Serge Saxonov said the deal reinforces the company’s commitment to make single cell analysis “routine, accessible, and scalable at levels previously unimaginable.” The acquisition also positions 10x to accelerate projects like the 100 Million Cell Challenge and Billion Cells Project, which require vast throughput without compromising on data richness.
By absorbing Scale’s inventions, 10x Genomics is expected to broaden its reach beyond elite research centers to a wider base of institutions and labs. This aligns with the company’s multi-year roadmap aimed at democratizing single cell and multiomic technologies for global adoption.
How did 10x Genomics perform in the second quarter of 2025 and what does it signal for investor sentiment?
Financially, 10x Genomics delivered Q2 2025 revenue of USD 172.9 million, though this figure includes a USD 27.3 million patent litigation settlement. Excluding that one-off item, adjusted revenue was USD 145.6 million. The company ended the quarter with USD 447.3 million in cash, cash equivalents, and marketable securities, an increase of USD 20 million over the prior quarter, signaling balance sheet resilience amid heavy R&D outlays.
Institutional investors have reacted with cautious optimism. While revenue growth was somewhat muted on an adjusted basis, the innovation cadence — new products, acquisitions, and partnerships — has reinforced confidence in 10x Genomics’ long-term positioning. Analysts broadly noted that the company is evolving from a product supplier to a multi-platform solutions provider in both single cell and spatial biology.
Shares of 10x Genomics (NASDAQ: TXG) showed modest gains following the announcements, with buy-side sentiment tilting toward “hold-to-accumulate” given the dual catalysts of product expansion and acquisition. The stock remains volatile, but analysts point to the company’s ability to expand its total addressable market in multiomics as a reason for maintaining medium-term confidence.
What role does the partnership with Singapore’s Genome Institute play in extending 10x Genomics’ platform reach?
Beyond its product and acquisition news, 10x Genomics recently unveiled a partnership with the Genome Institute of Singapore on the TISHUMAP initiative, which uses Xenium’s spatial biology capabilities and AI-powered analytics to identify novel cancer biomarkers and inflammatory disease targets.
The partnership underscores how 10x Genomics is embedding itself in large-scale precision medicine projects. By contributing both platform technology and informatics support, the company is increasing its relevance to national genomics programs that serve as testbeds for broader adoption.
Institutional observers believe that partnerships of this type serve dual functions: validating 10x’s platforms in global research ecosystems while also creating potential pipelines for pharmaceutical collaborations.
What is the future outlook for 10x Genomics as it builds an integrated multiomic ecosystem?
The combined momentum of Xenium Protein, the Scale Biosciences acquisition, and global partnerships suggests that 10x Genomics is positioning itself as a category leader in integrated multiomics. The company’s strategy focuses on three interconnected levers. First, it is deepening insights at the spatial level by integrating RNA and protein analysis, enabling researchers to capture a more comprehensive view of cellular interactions and disease mechanisms. Second, it is expanding throughput and affordability in single cell genomics through targeted acquisitions and product roadmaps, which are designed to make advanced tools more accessible to a wider research community. Finally, it is building strategic collaborations with international research hubs and pharmaceutical leaders, ensuring that its technologies are embedded in large-scale initiatives and aligned with translational applications in medicine.
Market watchers expect continued volatility in the short term, given the high capital intensity of biotech tools development. However, institutional sentiment points to growing conviction that 10x Genomics has achieved a defensible moat in spatial multiomics. The outlook remains constructive as the company seeks to translate its platform innovations into wider adoption across cancer research, immunology, neuroscience, and translational medicine.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
